Alzheimers Breakthrough: Donanemab and PBA Show Promise
Donanemab Slows Progression by 35%
A groundbreaking study has revealed that the drug donanemab can significantly slow the progression of Alzheimer's disease by 35% in patients. This remarkable finding has sparked optimism in the fight against this devastating neurodegenerative disorder.
PBA Restores Proteostasis
Another promising discovery involves the drug PBA. In mice that model Alzheimer's disease, injections of PBA helped to restore signs of normal proteostasis, the process by which cells maintain and regulate proteins. This suggests that PBA could potentially prevent or reverse the protein aggregation that is a hallmark of Alzheimer's.
Lecanemab Binds to Key Protein
Another monoclonal antibody, lecanemab, has also shown promising results. It works by binding to a key protein linked to Alzheimer's disease. This binding could help to reduce the accumulation of amyloid plaques, which are associated with the disease.
miBrain Models for Improved Drug Testing
Advancements in brain modeling are also contributing to the fight against Alzheimer's. miBrain models, which offer more realistic representations of brain tissue, allow for improved testing of drug candidates. This could accelerate the development of effective therapies.
Comments